Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Myovant Sciences acquired for $2.9 BLN on second offer

<< Previous

Bullboard Posts

Next >>

Comment by Lesalpes29on Oct 25, 2022 8:50am

88 Views

Post# 35046074

RE:RE:RE:RE:RE:RE:Myovant Sciences acquired for $2.9 BLN on second offer

fox7mf wrote: I feel $2.9b would be a fair offer that I certainly would not scoff at. Having said that, 2 ph3 trials, Car-T, and MM could all add up to a deal in the $4-$5b usd range. A buyout deal...no partnerships pls.

A deal at 20$ CAD and I'm retiring pronto! We can dream for sure. GL

<< Previous

Bullboard Posts

Next >>

Drilling company poised to capitalize on market conditions